Studieoverzicht

 
 
 
  2022-05 EMBER-4       Open       Adjuvant       HER2- HR+       Both pre- and postmenopausal  
  2021-02 ZEST       Active, not recruiting       Adjuvant       HER2-, any HR       Both pre- and postmenopausal  
  2017-02 PERIDENO       Closed       Adjuvant       HER2-, any HR       Postmenopausal  
  2016-03 PRECISE       Follow up       Adjuvant       Not applicable       Not applicable  
  2016-02 PALLAS       Follow up       Adjuvant       HER2- HR+       Both pre- and postmenopausal  
  2015-03 POSITIVE       Follow up       Adjuvant       Any HER2, HR+       Premenopausal  
  2014-03 OLYMPIA       Follow up       Adjuvant       HER2-, any HR       Both pre- and postmenopausal  
  2012-02 SafeHer       Follow up       Adjuvant       HER2+, any HR       Both pre- and postmenopausal  
  2011-02 APHINITY       Follow up       Adjuvant       HER2+, any HR       Both pre- and postmenopausal  
  2010-04 D-Care       Follow up       Adjuvant       Any HER2, any HR       Both pre- and postmenopausal  
  2008-01 2-2-6 G-CSF       Closed       Adjuvant       Any HER2, any HR       Both pre- and postmenopausal  
  2007-01 ALTTO       Closed       Adjuvant       HER2+, any HR       Both pre- and postmenopausal  
  2006-05 IDEAL       Follow up       Adjuvant       Any HER2, HR+       Postmenopausal  
  2006-04b TEAM IIb       Follow up       Adjuvant       Any HER2, HR+       Postmenopausal  
  2006-01 DATA       Closed       Adjuvant       Any HER2, HR+       Postmenopausal  
  2005-03 MINDACT       Follow up       Adjuvant       Any HER2, any HR       Both pre- and postmenopausal  
  2005-02 MATADOR       Follow up       Adjuvant       Any HER2, any HR       Both pre- and postmenopausal  
  2003-02 Calor       Closed       Adjuvant       Any HER2, any HR       Both pre- and postmenopausal  
  2002-04 HERA       Closed       Adjuvant       HER2+, any HR       Both pre- and postmenopausal  
  2001-01 TEAM       Closed       Adjuvant       Any HER2, HR+       Postmenopausal